Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer

Endocrine-Related Cancer

Volumn 20, Issue 2, 2013, Pages

  Leyssens, Carlien ^a   Verlinden, Lieve ^a   Verstuy, Annemieke ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Analog; Breast cancer; Colorectal cancer; Prostate cancer; Vitamin D

Indexed keywords

BETA CATENIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; CYTOCHROME; CYTOCHROME P450 24A1; CYTOCHROME P450 27B1; DOCETAXEL; PARICALCITOL; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR; WNT PROTEIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG STRUCTURE; HUMAN; INFLAMMATION; METASTASIS; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; VITAMIN INTAKE; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; VITAMIN D;

EID: 84876781055     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0381     Document Type: Review

References (190)

1. Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Fibbi B, Morelli A, UskokovicM, Colli E et al. 2007 Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). Journal of Steroid Biochemistry and Molecular Biology 103 689-693. (doi:10.1016/j.jsbmb.2006.12.065)
2. Aguilera O, Pena C, Garcia JM, Larriba MJ, Ordonez-Moran P, Navarro D, Barbachano A, Lopez de Silanes I, Ballestar E, FragaMF et al. 2007 TheWnt antagonist DICKKOPF-1 gene is induced by 1a,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 28 1877-1884. (doi:10.1093/carcin/bgm094)
3. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM et al. 2008 Serum vitamin D concentration and prostate cancer risk: a nested case-control study. Journal of the National Cancer Institute 100 796-804. (doi:10.1093/jnci/djn152)
4. Ahonen MH, Tenkanen L, Teppo L, HakamaM& Tuohimaa P 2000 Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes & Control 11 847-852. (doi:10.1023/A:1008923802001)
5. Almquist M, Bondeson AG, Bondeson L, Malm J & Manjer J 2010 Serum levels of vitamin D, PTH and calcium and breast cancer risk-A prospective nested case-control study. International Journal of Cancer 127 2159-2168. (doi:10.1002/ijc.25215)
6. Alvarez-Diaz S, Valle N, Garcia JM, Pena C, Freije JM, Quesada V, Astudillo A, Bonilla F, Lopez-Otin C & Munoz A 2009 Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. Journal of Clinical Investigation 119 2343-2358. (doi:10.1172/JCI37205)
7. Anderson LN, Cotterchio M, Kirsh VA & Knight JA 2011 Ultraviolet sunlight exposure during adolescence and adulthood and breast cancer risk: a population-based case-control study among Ontario women. American Journal of Epidemiology 174 293-304. (doi:10.1093/aje/kwr091)
8. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, Grant AM, Campbell MK, Anderson FH, Cooper C et al. 2011 Long-termfollow-up for mortality and cancer in a randomized placebocontrolled trial of vitamin D(3) and/or calcium (RECORD trial). Journal of Clinical Endocrinology and Metabolism 97 614-622. (doi:10.1210/jc.2011-1309)
9. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, DiPaola RS & Abate-Shen C 2006 Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clinical Cancer Research 12 5895-5901. (doi:10.1158/1078-0432.CCR-06-1039)
10. Bao BY, Yao J & Lee YF 2006a 1a,25-Dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27 1883-1893. (doi:10.1093/carcin/bgl041)
11. Bao BY, Yeh SD & Lee YF 2006b 1a,25-Dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 27 32-42. (doi:10.1093/carcin/bgi170)
12. Barbachano A, Ordonez-Moran P, Garcia JM, Sanchez A, Pereira F, Larriba MJ, Martinez N,Hernandez J, Landolfi S, Bonilla F et al. 2010 SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene 29 4800-4813. (doi:10.1038/onc.2010.225)
13. Bareis P, Bises G, Bischof MG, Cross HS & Peterlik M 2001 25-Hydroxyvitamin D metabolism in human colon cancer cells during tumor progression. Biochemical and Biophysical Research Communications 285 1012-1017. (doi:10.1006/bbrc.2001.5289)
14. Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, Hoffman AR, Barrett-Connor E, Orwoll E & Beer TM2010 Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes& Control 21 1297-1303. (doi:10.1007/s10552-010-9557-y)
15. Bastie CC, Gaffney-Stomberg E, LeeTW, Dhima E, Pessin JE & Augenlicht LH 2012Dietary cholecalciferol and calciumlevels inaWestern-style defined rodent diet alter energymetabolismand inflammatory responses in mice. Journal of Nutrition 142 859-865. (doi:10.3945/jn.111.149914)
16. Beer TM, Lemmon D, Lowe BA & HennerWD 2003 High-dose weekly oral calcitriol in patientswith a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97 1217-1224. (doi:10.1002/cncr.11179)
17. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM et al. 2007 Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. Journal of Clinical Oncology 25 669-674. (doi:10.1200/JCO.2006. 06.8197)
18. Belochitski O, Ariad S, Shany S, Fridman V & Gavrilov V 2007 Efficient dual treatment of the hormone-refractory prostate cancer cell line DU145 with cetuximab and 1,25-dihydroxyvitamin D3. In Vivo 21 371-376.
19. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y & Mabjeesh NJ 2007 1a,25-Dihydroxyvitamin D3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Molecular Cancer Therapeutics 6 1433-1439. (doi:10.1158/1535-7163.MCT-06-0677)
20. Bertone-JohnsonER,ChenWY,HolickMF,HollisBW,ColditzGA,WillettWC & Hankinson SE 2005 Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiology, Biomarkers & Prevention 14 1991-1997. (doi:10.1158/1055-9965.EPI-04-0722)
21. Bhatia V, Saini MK, Shen X, Bi LX, Qiu S, Weigel NL & Falzon M 2009 EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Molecular Cancer Therapeutics 8 1787-1798. (doi:10.1158/1535-7163.MCT-09-0064)
22. Bischoff-Ferrari HA 2008 Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Advances in Experimental Medicine and Biology 624 55-71. (doi:10.1007/978-0-387-77574-6-5)
23. Bises G, Kallay E, Weiland T, Wrba F, Wenzl E, Bonner E, Kriwanek S, Obrist P & Cross HS 2004 25-Hydroxyvitamin D3-1a-hydroxylase expression in normal and malignant human colon. Journal of Histochemistry and Cytochemistry 52 985-989. (doi:10.1369/jhc.4B6271.2004)
24. Bolland MJ, Grey A, Gamble GD & Reid IR 2011 Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-Access data set. American Journal of Clinical Nutrition 94 1144-1149. (doi:10.3945/ajcn.111.015032)
25. Boscoe FP & Schymura MJ 2006 Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 6 264. (doi:10.1186/1471-2407-6-264)
26. Bouillon R 2011Why modest but widespread improvement of the vitamin D status is the best strategyBest Practice & Research. Clinical Endocrinology& Metabolism 25 693-702. (doi:10.1016/j.beem.2011.06.008)
27. Chen A, Davis BH, Sitrin MD, Brasitus TA & Bissonnette M 2002 Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3). American Journal of Physiology. Gastrointestinal and Liver Physiology 283 G864-G874.
28. Chen TC, Persons KS, Zheng S, Mathieu J, Holick MF, Lee YF, Bao B, Arai MA & Kittaka A 2007 Evaluation of C-2-substituted 19-nor-1a,25- dihydroxyvitamin D3 analogs as therapeutic agents for prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 103 717-720. (doi:10.1016/j.jsbmb. 2006.12.009)
29. Chen Y, Kong J, Sun T, Li G, Szeto FL, Liu W, Deb DK, Wang Y, Zhao Q, Thadhani R et al. 2010 1,25-Dihydroxyvitamin D(3) suppresses inflammation-induced expression of plasminogen activator inhibitor-1 by blocking nuclear factor-kappaB activation. Archives of Biochemistry and Biophysics 507 241-247. (doi:10.1016/j.abb.2010.12.020)
30. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S et al. 2008 Calcium plus vitamin D supplementation and the risk of breast cancer. Journal of the National Cancer Institute 100 1581-1591. (doi:10.1093/jnci/djn360)
31. Choo CS, Mamedov A, Chung M, Choo R, Kiss A & Danjoux C 2011 Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer. Nutrition Research 31 21-26. (doi:10.1016/j.nutres. 2010.12.007)
32. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL & Johnson CS 2009 Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Research 69 967-975. (doi:10.1158/0008-5472.CAN-08-2307)
33. Colston K, Colston MJ & Feldman D 1981 1,25-Dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108 1083-1086. (doi:10.1210/endo-108-3-1083)
34. Cross HS, Bareis P, Hofer H, Bischof MG, Bajna E, Kriwanek S, Bonner E & PeterlikM2001 25-Hydroxyvitamin D(3)-1a-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 66 287-292. (doi:10.1016/S0039-128X(00)00153-7)
35. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB & NelsonWG 2007 Inflammation in prostate carcinogenesis. Nature Reviews. Cancer 7 256-269. (doi:10.1038/nrc2090)
36. Diaz GD, Paraskeva C, Thomas MG, Binderup L & Hague A 2000 Apoptosis is induced by the active metabolite of vitamin D3 and its analog EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Research 60 2304-2312.
37. von Domarus C, Brown J, Barvencik F, Amling M & Pogoda P 2011 How much vitamin D do we need for skeletal healthClinical Orthopaedics and Related Research 469 3127-3133. (doi:10.1007/s11999-011-1880-4)
38. Dyson JK & Rutter MD 2012 Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the riskWorld Journal of Gastroenterology 18 3839-3848. (doi:10.3748/wjg.v18.i29.3839)
39. Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC & Clavel-Chapelon F 2010 Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiology, Biomarkers & Prevention 19 2341-2350. (doi:10.1158/1055-9965.EPI-10-0264)
40. van Etten E, Stoffels K, Gysemans C, Mathieu C & Overbergh L 2008 Regulation of vitamin D homeostasis: implications for the immune system. Nutrition Reviews 66 S125-S134. (doi:10.1111/j.1753-4887.00096.x)
41. Evans SR, Shchepotin EI, Young H, Rochon J, UskokovicM& Shchepotin IB 2000 1,25-Dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model. International Journal of Oncology 16 1249-1254.
42. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, Ma J, Gaziano JM, Stampfer MJ, Mucci LA et al. 2011 Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS ONE 6 e18625. (doi:10.1371/journal.pone.0018625)
43. Fedirko V, Bostick RM, Flanders WD, Long Q, Shaukat A, Rutherford RE, Daniel CR, Cohen V & Dash C 2009a Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prevention Research 2 213-223. (doi:10.1158/1940-6207.CAPR-08-0157)
44. Fedirko V, Bostick RM, Flanders WD, Long Q, Sidelnikov E, Shaukat A, Daniel CR, Rutherford RE & Woodard JJ 2009b Effects of vitamin D and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial. Cancer Epidemiology, Biomarkers & Prevention 18 2933-2941. (doi:10.1158/1055-9965.EPI-09-0239)
45. Fedirko V, Bostick RM, Goodman M, FlandersWD& GrossMD2010a Blood 25-hydroxyvitamin D3 concentrations and incident sporadic colorectal adenoma risk: a pooled case-control study. American Journal of Epidemiology 172 489-500. (doi:10.1093/aje/kwq157)
46. Fedirko V, Bostick RM, Long Q, FlandersWD, McCulloughML, Sidelnikov E, Daniel CR, Rutherford RE & Shaukat A 2010b Effects of supplemental vitamin D and calcium on oxidative DNA damagemarker in normal colorectalmucosa: a randomized clinical trial. Cancer Epidemiology, Biomarkers&Prevention 19 280-291. (doi:10.1158/1055-9965.EPI-09-0448)
47. Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez-Martin A, del Rio M, Barettino D, Volpert O, Munoz A & Jimenez B 2005 1a,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene 24 6533-6544. (doi:10.1038/sj.onc.1208801)
48. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW & Giovannucci EL 2004 Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiology, Biomarkers & Prevention 13 1502-1508.
49. Fiscella K, Winters P, Tancredi D, Hendren S & Franks P 2010 Racial disparity in death from colorectal cancer: does vitamin D deficiency contributeCancer 117 1061-1069. (doi:10.1002/cncr.25647)
50. Fischer D, Becker S, Cordes T, Bucker B, Diedrich K, Friedrich M, Salehin D & Thill M 2009 Vitamin D-24-hydroxylase in benign and malignant breast tissue and cell lines. Anticancer Research 29 3641-3645.
51. Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF & Chen TC 2006 Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Research 26 2567-2572.
52. Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD & Ziegler RG 2008 Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiology, Biomarkers & Prevention 17 889-894. (doi:10.1158/1055-9965.EPI-07-2594)
53. Freedman DM, Looker AC, Abnet CC, Linet MS & Graubard BI 2010 Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Research 70 8587-8597. (doi:10.1158/0008-5472.CAN-10-1420)
54. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P & Autier P 2010 Meta-Analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. International Journal of Cancer 128 1414-1424. (doi:10.1002/ijc.25439)
55. Garland CF & Garland FC 1980 Do sunlight and vitamin D reduce the likelihood of colon cancerInternational Journal of Epidemiology 9 227-231. (doi:10.1093/ije/9.3.227)
56. Gilbert R, Metcalfe C, Oliver SE, Whiteman DC, Bain C, Ness A, Donovan J, Hamdy F, Neal DE, Lane JA et al. 2009 Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-Analysis. International Journal of Cancer 125 1414-1423. (doi:10.1002/ijc.24411)
57. Golovko O, Nazarova N & Tuohimaa P 2005 Vitamin D-induced up-regulation of tumour necrosis factor a (TNF-A) in prostate cancer cells. Life Sciences 77 562-577. (doi:10.1016/j.lfs.2004.10.072)
58. Goodwin PJ, EnnisM, Pritchard KI, Koo J & Hood N 2009 Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. Journal of Clinical Oncology 27 3757-3763. (doi:10.1200/JCO.2008.20.0725)
59. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M & Holick MF 2005 Vitamin D and prevention of colorectal cancer. Journal of Steroid Biochemistry and Molecular Biology 97 179-194. (doi:10.1016/j.jsbmb.2005.06.018)
60. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M & Holick MF 2007 Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. American Journal of Preventive Medicine 32 210-216. (doi:10.1016/j.amepre.2006.11.004)
61. Grant WB 2002 An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 94 1867-1875. (doi:10.1002/cncr.10427)
62. Grant WB 2011 An ecological study of cancer incidence and mortality rates in France with respect to latitude, an index for vitamin D production. Dermato-Endocrinology 2 62-67. (doi:10.4161/derm.2.2.13624)
63. Guzey M, Kitada S & Reed JC 2002 Apoptosis induction by 1a,25-dihydroxyvitamin D3 in prostate cancer. Molecular Cancer Therapeutics 1 667-677.
64. Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, Brouckaert O, Peuteman G, Laenen A, Verlinden L et al. 2012 Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis 33 1319-1326. (doi:10.1093/carcin/bgs187)
65. Hollis BW 2009 Nutrition: US recommendations fail to correct vitamin D deficiency. Nature Reviews. Endocrinology 5 534-536. (doi:10.1038/nrendo.2009. 178)
66. Hsu JW, Yasmin-Karim S, King MR, Wojciechowski JC, Mickelsen D, Blair ML, Ting HJ, Ma WL & Lee YF 2011 Suppression of prostate cancer cell rolling and adhesion to endothelium by 1a,25-dihydroxyvitamin D3. American Journal of Pathology 178 872-880. (doi:10.1016/j.ajpath.2010.10.036)
67. Huang YC & Hung WC 2006 1,25-Dihydroxyvitamin D3 transcriptionally represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells. Journal of Cellular Physiology 209 363-369. (doi:10.1002/jcp. 20741)
68. Hummel DM, Thiem U, Hobaus J,Mesteri I, Gober L, Stremnitzer C, Graca J, Obermayer-Pietsch B & Kallay E 2012 Prevention of preneoplastic lesions by dietary vitamin D in a mousemodel of colorectal carcinogenesis. Journal of Steroid Biochemistry and Molecular Biology [in press]. (doi:10.1016/j.jsbmb. 2012.09.003)
69. Iglesias-Gato D, Zheng S, Flanagan JN, Jiang L, Kittaka A, Sakaki T, Yamamoto K, Itoh T, Lebrasseur NK, Norstedt G et al. 2011 Substitution at carbon 2 of 19-nor-1a,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analog with enhanced chemotherapeutic potency in PC-3 prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology 127 269-275. (doi:10.1016/j.jsbmb. 2011.08.010)
70. Jacobs ET, Thomson CA, Flatt SW, Al-Delaimy WK, Hibler EA, Jones LA, Leroy EC, Newman VA, Parker BA, Rock CL et al. 2010 Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. American Journal of Clinical Nutrition 93 108-117. (doi:10.3945/ajcn.2010.30009)
71. James SY, Mackay AG & Colston KW1996 Effects of 1,25 dihydroxyvitamin D3 and its analogs on induction of apoptosis in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 58 395-401. (doi:10.1016/0960- 0760(96)00048-9)
72. Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, Jansen EH, Slimani N, Byrnes G, Rinaldi S et al. 2010 Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 340 b5500. (doi:10.1136/bmj.b5500)
73. Jensen SS, Madsen MW, Lukas J, Binderup L & Bartek J 2001 Inhibitory effects of 1a,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Molecular Endocrinology 15 1370-1380. (doi:10.1210/me.15.1370)
74. John EM, Schwartz GG, Dreon DM & Koo J 1999 Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiology, Biomarkers & Prevention 8 399-406.
75. John EM, Koo J & Schwartz GG 2007 Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiology, Biomarkers & Prevention 16 1283-1286. (doi:10.1158/1055-9965. EPI-06-1053)
76. Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer C, Kato S & Cross HS 2001 Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 22 1429-1435. (doi:10.1093/carcin/22.9.1429)
77. Kallay E, Bises G, Bajna E, Bieglmayer C, Gerdenitsch W, Steffan I, Kato S, Armbrecht HJ & Cross HS 2005 Colon-specific regulation of vitamin D hydroxylases -A possible approach for tumor prevention. Carcinogenesis 26 1581-1589. (doi:10.1093/carcin/bgi124)
78. Kemmis CM & Welsh J 2008 Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. Journal of Cellular Biochemistry 105 980-988. (doi:10.1002/jcb.21896)
79. Kemmis CM, Salvador SM, Smith KM & Welsh J 2006 Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. Journal of Nutrition 136 887-892.
80. Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl DM, Stewart PM, Turner BM et al. 2004 Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene 23 6712-6725. (doi:10.1038/sj.onc.1207772)
81. Koike H, Morikawa Y, Sekine Y, Matsui H, Shibata Y & Suzuki K 2011 Survivin is associated with cell proliferation and has a role in 1a,25-dihydroxyvitamin D3 induced cell growth inhibition in prostate cancer. Journal of Urology 185 1497-1503. (doi:10.1016/j.juro.2010.12.005)
82. Koli K & Keski-Oja J 2000 1a,25-Dihydroxyvitamin D3 and its analogues down-regulate cell invasion-Associated proteases in cultured malignant cells. Cell Growth and Differentiation 11 221-229.
83. Koren R, Wacksberg S, Weitsman GE & Ravid A 2006 Calcitriol sensitizes colon cancer cells to H2O2-induced cytotoxicity while inhibiting caspase activation. Journal of Steroid Biochemistry and Molecular Biology 101 151-160. (doi:10.1016/j.jsbmb.2006.06.013)
84. Kouchi Z, Fujiwara Y, Yamaguchi H, Nakamura Y & Fukami K 2011 Phosphatidylinositol 5-phosphate 4-kinase type II beta is required for vitamin D receptor-dependent E-cadherin expression in SW480 cells. Biochemical and Biophysical Research Communications 408 523-529. (doi:10.1016/j.bbrc.2011.04. 045)
85. Kovalenko PL, Zhang Z, Cui M, Clinton SK & Fleet JC 2010 1,25-Dihydroxyvitamin D-mediated orchestration of anticancer, transcriptlevel effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics 11 26. (doi:10.1186/1471-2164-11-26)
86. Kovalenko PL, Zhang Z, Yu JG, Li Y, Clinton SK & Fleet JC 2011 Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate. Cancer Prevention Research 4 1617-1625. (doi:10.1158/1940-6207.CAPR-11-0035)
87. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM & Feldman D 2004 Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59 243-251. (doi:10.1002/pros.20006)
88. Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM & Feldman D 2007 Novel pathways that contribute to the antiproliferative and chemopreventive activities of calcitriol in prostate cancer. Journal of Steroid Biochemistry andMolecular Biology 103 694-702. (doi:10.1016/j.jsbmb.2006.12.051)
89. Kurihara N, Fan K, Thaler HT, Yang K & Lipkin M 2008 Effect of a westernstyle diet fortified with increased calcium and vitamin D on mammary gland of C57BL/6 mice. Journal of Medicinal Food 11 201-206. (doi:10.1089/jmf.2007.619)
90. LaCroix AZ, Kotchen J, Anderson G, Brzyski R, Cauley JA, Cummings SR, Gass M, Johnson KC, Ko M, Larson J et al. 2009 Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 64 559-567. (doi:10.1093/gerona/glp006)
91. Larriba MJ, Ordonez-Moran P, Chicote I, Martin-Fernandez G, Puig I, Munoz A & Palmer HG 2011 Vitamin D receptor deficiency enhances Wnt/beta-catenin signaling and tumor burden in colon cancer. PLoS ONE 6 e23524. (doi:10.1371/journal.pone.0023524)
92. Larsson D, Hagberg M, Malek N, Kjellberg C, Senneberg E, Tahmasebifar N & Johansson V 2008 Membrane initiated signaling by 1,25a-dihydroxyvitamin D3 in LNCaP prostate cancer cells. Advances in Experimental Medicine and Biology 617 573-579. (doi:10.1007/978-0-387-69080-3-59)
93. LeeHJ, LiuH,GoodmanC, Ji Y,MaehrH,UskokovicM,Notterman D, ReissM & Suh N 2006 Gene expression profiling changes induced by a novel gemini vitamin D derivative during the progression of breast cancer. Biochemical Pharmacology 72 332-343. (doi:10.1016/j.bcp.2006.04.030)
94. LeeHJ, Paul S, Atalla N, Thomas PE, Lin X, Yang I, Buckley B, Lu G, Zheng X, Lou YR et al. 2008 Gemini vitaminDanalogues inhibit estrogen receptorpositive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prevention Research 1 476-484. (doi:10.1158/1940-6207.CAPR-08-0084)
95. LeeHJ, So JY,DeCastro A,Smolarek A, Paul S,MaehrH,UskokovicM&SuhN 2010 Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. Journal of Steroid Biochemistry and Molecular Biology 121 408-412. (doi:10.1016/j.jsbmb.2010.03.053)
96. Lee JE, Li H,ChanAT,HollisBW, Lee IM, StampferMJ,WuK, GiovannucciE& Ma J 2011 Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-Analysis of prospective studies. Cancer Prevention Research 4 735-743. (doi:10.1158/1940-6207.CAPR-10-0289)
97. Leidig-Bruckner G, Roth HJ, Bruckner T, Lorenz A, Raue F & Frank-Raue K 2010 Are commonly recommended dosages for vitamin D supplementation too lowVitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels -An observational study during clinical practice conditions Osteoporosis International 22 231-240. (doi:10.1007/s00198-010-1214-5)
98. Li F, Ling X, HuangH, Brattain L, Apontes P,WuJ, Binderup L&BrattainMG 2005 Differential regulation of survivin expression and apoptosis by vitaminD3 compounds in two isogenicMCF-7 breast cancer cell sublines. Oncogene 24 1385-1395. (doi:10.1038/sj.onc.1208330)
99. LiH,StampferMJ,Hollis JB,MucciLA,GazianoJM,HunterD,Giovannucci EL &Ma J2007Aprospective studyof plasma vitaminDmetabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Medicine 4 e103. (doi:10.1371/journal. pmed.0040103)
100. Lin J, Manson JE, Lee IM, Cook NR, Buring JE & Zhang SM 2007 Intakes of calcium and vitamin D and breast cancer risk in women. Archives of Internal Medicine 167 1050-1059. (doi:10.1001/archinte.167.10.1050)
101. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL & Schmitt F 2010 Alterations in Vitamin D signaling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10 483. (doi:10.1186/1471-2407-10-483)
102. Malloy PJ & Feldman D 2009 Inactivation of the human vitamin D receptor by caspase-3. Endocrinology 150 679-686. (doi:10.1210/en.2008-1217)
103. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, Ambrose LH, Kindy MS & Gattoni-Celli S 2012 Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. Journal of Clinical Endocrinology and Metabolism 97 2315-2324. (doi:10.1210/jc.2012-1451)
104. Matilainen JM, Malinen M, Turunen MM, Carlberg C & Vaisanen S 2010 The number of vitamin D receptor binding sites defines the different vitamin D responsiveness of the CYP24 gene in malignant and normal mammary cells. Journal of Biological Chemistry 285 24174-24183. (doi:10.1074/jbc.M110.124073)
105. Matusiak D & Benya RV 2007 CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. Journal of Histochemistry and Cytochemistry 55 1257-1264. (doi:10.1369/jhc.7A7286.2007)
106. Matusiak D, Murillo G, Carroll RE, Mehta RG & Benya RV 2005 Expression of vitamin D receptor and 25-hydroxyvitamin D3-1a-hydroxylase in normal and malignant human colon. Cancer Epidemiology, Biomarkers & Prevention 14 2370-2376. (doi:10.1158/1055-9965.EPI-05-0257)
107. McCarthy K, Laban C, Bustin SA, Ogunkolade W, Khalaf S, Carpenter R & Jenkins PJ 2009 Expression of 25-hydroxyvitamin D-1-A-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue. Anticancer Research 29 155-157.
108. McCulloughML, StevensVL, PatelR, JacobsEJ, BainEB,HorstRL,GapsturSM, Thun MJ & Calle EE 2009 Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Research 11 R64. (doi:10.1186/bcr2356)
109. McGaffin KR & Chrysogelos SA 2005 Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. Journal of Molecular Endocrinology 35 117-133. (doi:10.1677/jme.1.
110. McGuire TF, Trump DL & Johnson CS 2001 Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. Journal of Biological Chemistry 276 26365-26373. (doi:10.1074/jbc. M010101200)
111. Merchiers P, Bulens F, Stockmans I, De Vriese A, Convents R, Bouillon R, Collen D, Belayew A & Carmeliet G 1999 1,25-Dihydroxyvitamin D(3) induction of the tissue-type plasminogen activator gene is mediated through its multihormone-responsive enhancer. FEBS Letters 460 289-296. (doi:10.1016/S0014- 5793(99)01337-X)
112. Millen AE, Wactawski-Wende J, Pettinger M, Melamed ML, Tylavsky FA, Liu S, Robbins J, LaCroix AZ, LeBoffMS & Jackson RD 2010 Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. American Journal of Clinical Nutrition 91 1324-1335. (doi:10.3945/ajcn.2009.28908)
113. Milliken EL, Zhang X, Flask C, Duerk JL, MacDonald PN & Keri RA 2005 EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Letters 229 205-215. (doi:10.1016/j. canlet.2005.06.044)
114. Mohr SB, Garland CF, Gorham ED, Grant WB & Garland FC 2008 Relationship between low ultraviolet B irradiance and higher breast cancer risk in 107 countries. Breast Journal 14 255-260. (doi:10.1111/j. 1524-4741.2008.00571.x)
115. Mordan-McCombs S, Brown T, Wang WL, Gaupel AC, Welsh J & Tenniswood M 2010 Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. Journal of Steroid Biochemistry and Molecular Biology 121 368-371. (doi:10.1016/j.jsbmb.2010.03. 062)
116. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM & Feldman D 2005 Regulation of prostaglandinmetabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Research 65 7917-7925. (doi:10.1158/0008-5472.CAN-05-0884)
117. Morris MJ, Smaletz O, Solit D, Kelly WK, Slovin S, Flombaum C, Curley T, Delacruz A, Schwartz L, Fleisher M et al. 2004 High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer 100 1868-1875. (doi:10.1002/cncr.20185)
118. Murphy AB,Kelley B,Nyame YA,Martin IK, Smith DJ, Castaneda L, ZagajaGJ, Hollowell CM & Kittles RA 2012 Predictors of serum vitamin D levels in African American and European American men in Chicago. American Journal of Men's Health 6 420-426. (doi:10.1177/1557988312437240)
119. Napoli N, Vattikuti S, Ma C, Rastelli A, Rayani A, Donepudi R, Asadfard M, Yarramaneni J, Ellis M & Armamento-Villareal R 2010 High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer. Breast Journal 16 609-616. (doi:10.1111/j.1524-4741.01012.x)
120. Nazarova N, Golovko O, Blauer M & Tuohimaa P 2005 Calcitriol inhibits growth response to platelet-derived growth factor-BB in human prostate cells. Journal of Steroid Biochemistry and Molecular Biology 94 189-196. (doi:10.1016/j.jsbmb.2005.01.017)
121. Newmark HL, Yang K, Kurihara N, Fan K, Augenlicht LH & Lipkin M 2009 Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis 30 88-92. (doi:10.1093/carcin/bgn229)
122. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL & Fuchs CS 2008 Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. Journal of Clinical Oncology 26 2984-2991. (doi:10.1200/JCO.2007.15.1027)
123. Nonn L, Peng L, FeldmanD&PeehlDM2006 Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogenactivated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Research 66 4516-4524. (doi:10.1158/0008-5472.CAN-05-3796)
124. Oades GM, Dredge K, Kirby RS & Colston KW 2002 Vitamin D receptordependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU International 90 607-616. (doi:10.1046/j.1464-410X.2002.02964.x)
125. Ogunkolade BW, Boucher BJ, Fairclough PD, HitmanGA,Dorudi S, Jenkins PJ & Bustin SA 2002 Expression of 25-hydroxyvitamin D-1-A-hydroxylase mRNA in individuals with colorectal cancer. Lancet 359 1831-1832. (doi:10.1016/S0140- 6736(02)08680-4)
126. Oh K, Willett WC, Wu K, Fuchs CS & Giovannucci EL 2007 Calcium and vitamin D intakes in relation to risk of distal colorectal adenoma in women. American Journal of Epidemiology 165 1178-1186. (doi:10.1093/aje/kwm026)
127. Okamoto R, Delansorne R,Wakimoto N, Doan NB, Akagi T, ShenM, Ho QH, Said JW & Koeffler HP 2011 Inecalcitol, an analog of 1a,25(OH)(2) D(3), induces growth arrest of androgen-dependent prostate cancer cells. International Journal of Cancer 130 2464-2473. (doi:10.1002/ijc.26279)
128. Ooi LL, Zhou H, Kalak R, Zheng Y, Conigrave AD, Seibel MJ & Dunstan CR 2010 Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Research 70 1835-1844. (doi:10.1158/0008-5472. CAN-09-3194)
129. Ordonez-Moran P, Larriba MJ, Palmer HG, Valero RA, Barbachano A, Dunach M, de Herreros AG, Villalobos C, Berciano MT, Lafarga M et al. 2008 RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. Journal of Cell Biology 183 697-710. (doi:10.1083/jcb.200803020)
130. Otani T, IwasakiM, Sasazuki S, InoueM& Tsugane S 2007 Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. British Journal of Cancer 97 446-451. (doi:10.1038/sj.bjc. 6603892)
131. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M et al. 2001 Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. Journal of Cell Biology 154 369-387. (doi:10.1083/jcb.200102028)
132. ParkWH, Seol JG,KimES,HyunJM, JungCW, LeeCC, BinderupL,KoefflerHP, KimBK & Lee YY 2000a Induction of apoptosis by vitamin D3 analog EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. British Journal of Haematology 109 576-583. (doi:10.1046/j.1365-2141.2000.02046.x)
133. ParkWH, Seol JG, KimES, JungCW, Lee CC, Binderup L, KoefflerHP, KimBK & Lee YY 2000b Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Experimental Cell Research 254 279-286. (doi:10.1006/excr.1999.4735)
134. Pike JW 2011 Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand. Molecular and Cellular Endocrinology 347 3-10. (doi:10.1016/j.mce.2011.05.012)
135. Pramyothin P & Holick MF 2012 Vitamin D supplementation: guidelines and evidence for subclinical deficiency. Current Opinion in Gastroenterology 28 139-150. (doi:10.1097/MOG.0b013e32835004dc)
136. Ray R, Banks M, Abuzahra H, Eddy VJ, Persons KS, Lucia MS, Lambert JR & Holick MF 2012 Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model. Anticancer Research 32 727-731.
137. Reddy S, Shapiro M, Morton R, Jr. & Brawley OW 2003 Prostate cancer in black and white Americans. Cancer Metastasis Reviews 22 83-86. (doi:10.1023/A:1022216119066)
138. Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L & Mosekilde L 2009 Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiology, Biomarkers & Prevention 18 2655-2660. (doi:10.1158/1055-9965.EPI-09-0531)
139. Rohan TE, Negassa A, Chlebowski RT, Ceria-UlepCD, Cochrane BB, Lane DS, Ginsberg M, Wassertheil-Smoller S & Page DL 2009 A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Research and Treatment 116 339-350. (doi:10.1007/s10549-008-0213-0)
140. Scaglione-Sewell BA, Bissonnette M, Skarosi S, Abraham C & Brasitus TA 2000 A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Endocrinology 141 3931-3939. (doi:10.1210/en.141.11.3931)
141. Scher HI, Jia X, Chi K, de Wit R, BerryWR, Albers P, Henick B,Waterhouse D, Ruether DJ, Rosen PJ et al. 2011 Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. Journal of Clinical Oncology 29 2191-2198. (doi:10.1200/JCO.2010.32.8815)
142. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J & Torti FM 2005 Phase I/II study of 19-nor-1a-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clinical Cancer Research 11 8680-8685. (doi:10.1158/1078-0432.CCR-05-1237)
143. Sergeev IN 2004 Calcium as a mediator of 1,25-dihydroxyvitamin D3-induced apoptosis. Journal of Steroid Biochemistry and Molecular Biology 89-90 419-425. (doi:10.1016/j.jsbmb.2004.03.010)
144. Shi H, Yan PS, Chen CM, Rahmatpanah F, Lofton-Day C, Caldwell CW & Huang TH 2002 Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Research 62 3214-3220.
145. ShuiIM,Mucci LA,Kraft P, TamimiRM, LindstromS, PenneyKL,NimptschK, Hollis BW, Dupre N, Platz EA et al. 2012 Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. Journal of the National Cancer Institute 104 690-699. (doi:10.1093/jnci/djs189)
146. Sidelnikov E, Bostick RM, Flanders WD, Long Q, Fedirko V, Shaukat A, Daniel CR & Rutherford RE 2010 Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients. Cancer Epidemiology, Biomarkers & Prevention 19 1022-1032. (doi:10.1158/1055-9965. EPI-09-0526)
147. Simboli-Campbell M, Narvaez CJ, Tenniswood M & Welsh J 1996 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 58 367-376. (doi:10.1016/0960-0760(96)00055-6)
148. Spina CS, Ton L, Yao M, Maehr H, Wolfe MM, Uskokovic M, Adorini L & Holick MF 2007 Selective vitamin D receptor modulators and their effects on colorectal tumor growth. Journal of Steroid Biochemistry and Molecular Biology 103 757-762. (doi:10.1016/j.jsbmb.2006.12.040)
149. Stio M, Martinesi M, Simoni A, Zuegel U, Steinmeyer A, Santi R, Treves C & Nesi G 2011 The novel vitamin D analog ZK191784 inhibits prostate cancer cell invasion. Anticancer Research 31 4091-4098.
150. Sun J, Mustafi R, Cerda S, Chumsangsri A, Xia YR, Li YC & Bissonnette M 2008 Lithocholic acid down-regulation of NF-kappaB activity through vitamin D receptor in colonic cancer cells. Journal of Steroid Biochemistry and Molecular Biology 111 37-40. (doi:10.1016/j.jsbmb.2008.01.003)
151. Sung V & Feldman D 2000 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Molecular and Cellular Endocrinology 164 133-143. (doi:10.1016/S0303-7207(00)00226-4)
152. Swami S, Raghavachari N, Muller UR, Bao YP & Feldman D 2003 Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Research and Treatment 80 49-62. (doi:10.1023/A:1024487118457)
153. Swami S, Krishnan AV, Wang JY, Jensen K, Horst R, Albertelli MA & Feldman D 2012 Dietary vitamin D(3) and 1,25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 153 2576-2587. (doi:10.1210/en.2011-1600)
154. Tagami T, Lutz WH, Kumar R & Jameson JL 1998 The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochemical and Biophysical Research Communications 253 358-363. (doi:10.1006/bbrc.1998.9799)
155. Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM & Holick MF 2005 Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. Journal of Nutrition 135 2350-2354.
156. Tavera-Mendoza L, Wang TT, Lallemant B, Zhang R, Nagai Y, Bourdeau V, Ramirez-Calderon M, Desbarats J,Mader S&White JH2006Convergence of vitaminDand retinoic acid signalling at a common hormone response element. EMBO Reports 7 180-185. (doi:10.1038/sj.embor.7400594)
157. Thill M, Fischer D, Becker S, Cordes T, Dittmer C, Diedrich K, Salehin D & Friedrich M 2009 Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines. Anticancer Research 29 3619-3625.
158. Thill M, Fischer D, Hoellen F, Kelling K, Dittmer C, Landt S, Salehin D, Diedrich K, Friedrich M & Becker S 2010 Prostaglandin metabolising enzymes and PGE2 are inversely correlated with vitamin D receptor and 25(OH)2D3 in breast cancer. Anticancer Research 30 1673-1679.
159. Ting HJ, Bao BY, Reeder JE,MessingEM&Lee YF 2007 Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1a,25-dihydroxyvitamin D3 responsiveness. Molecular Cancer Research 5 967-980. (doi:10.1158/1541-7786.MCR-06-0318)
160. Tokar EJ & Webber MM 2005 Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clinical & Experimental Metastasis 22 275-284. (doi:10.1007/s10585-005-8393-z)
161. Travis RC,Crowe FL,Allen NE,Appleby PN,RoddamAW, TjonnelandA, OlsenA, Linseisen J, Kaaks R, Boeing H et al. 2009 Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). American Journal of Epidemiology 169 1223-1232. (doi:10.1093/aje/kwp022)
162. Tse AK, Zhu GY, Wan CK, Shen XL, Yu ZL & Fong WF 2010 1a,25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. Molecular Immunology 47 1728-1738. (doi:10.1016/j.molimm.2010.03.004)
163. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T et al. 2004 Both highand low levels of blood vitaminD are associatedwith a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. International Journal of Cancer 108 104-108. (doi:10.1002/ijc.11375)
164. Verlinden L, Verstuyf A, Van Camp M, Marcelis S, Sabbe K, Zhao XY, De Clercq P, VandewalleM& Bouillon R 2000 Two novel 14-Epi-Analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Research 60 2673-2679.
165. Verlinden L, Eelen G, Beullens I, Van CampM, Van Hummelen P, Engelen K, Van Hellemont R, Marchal K, De Moor B, Foijer F et al. 2005 Characterization of the condensin component Cnap1 and protein kinase Melk as novel E2F target genes down-regulated by 1,25-dihydroxyvitamin D3. Journal of Biological Chemistry 280 37319-37330. (doi:10.1074/jbc. M503587200)
166. Verlinden L, Eelen G, Van Hellemont R, Engelen K, Beullens I, Van CampM, Marchal K, Mathieu C, Bouillon R & Verstuyf A 2007 1a,25-Dihydroxyvitamin D3-induced down-regulation of the checkpoint proteins, Chk1 and Claspin, ismediated by the pocket proteins p107 and p130. Journal of Steroid Biochemistry and Molecular Biology 103 411-415. (doi:10.1016/j.jsbmb.2006.12.080)
167. Vrieling A, Hein R, Abbas S, Schneeweiss A, Flesch-JanysD & Chang-Claude J 2011 Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospectivepatient cohort study. BreastCancer Research13R74. (doi:10.1186/bcr2920)
168. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L et al. 2006 Calcium plus vitamin D supplementation and the risk of colorectal cancer. New England Journal of Medicine 354 684-696. (doi:10.1056/NEJMoa055222)
169. Wade WN, Willingham MC, Koumenis C & Cramer SD 2002 p27Kip1 is essential for the antiproliferative action of 1,25-dihydroxyvitamin D3 in primary, but not immortalized, mouse embryonic fibroblasts. Journal of Biological Chemistry 277 37301-37306. (doi:10.1074/jbc.M204162200)
170. Wagner N, Wagner KD, Schley G, Badiali L, Theres H & Scholz H 2003 1,25-Dihydroxyvitamin D3-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Experimental Eye Research 77 1-9. (doi:10.1016/S0014-4835(03)00108-8)
171. Wang QM, Luo X & Studzinski GP 1997 Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells. Cancer Research 57 2851-2855.
172. Wasan HS, Park HS, Liu KC, Mandir NK, Winnett A, Sasieni P, Bodmer WF, Goodlad RA &Wright NA 1998 APC in the regulation of intestinal crypt fission. Journal of Pathology 185 246-255. (doi:10.1002/(SICI)1096-9896(199807) 185:3!246::AID-PATH90O3.0.CO;2-8)
173. Washington MN, Kim JS &Weigel NL 2010 1a,25-Dihydroxyvitamin D3 inhibitsC4-2prostate cancer cell growthvia a retinoblastomaprotein(Rb)- independent G1 arrest. Prostate 71 98-110. (doi:10.1002/pros.21226)
174. WeiMY, Garland CF,GorhamED,Mohr SB&Giovannucci E 2008 VitaminD and prevention of colorectal adenoma: a meta-Analysis. Cancer Epidemiology, Biomarkers & Prevention 17 2958-2969. (doi:10.1158/1055-9965.EPI-08-0402)
175. Weinstein SJ, Yu K, Horst RL, Ashby J, Virtamo J & Albanes D 2011 Serum 25-hydroxyvitaminDand risks of colon and rectal cancer inFinnishmen. American Journal of Epidemiology 173 499-508. (doi:10.1093/aje/kwq398)
176. Weitsman GE, Ravid A, Liberman UA & Koren R 2004 The role of p38 MAP kinase in the synergistic cytotoxic action of calcitriol and TNF-A in human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 89-90 361-364. (doi:10.1016/j.jsbmb.2004.03.019)
177. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF & Chen TC 2002 25-Hydroxyvitamin D-1a-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. Journal of Steroid Biochemistry and Molecular Biology 81 135-140. (doi:10.1016/S0960-0760(02)00053-5)
178. Woo TC, Choo R, Jamieson M, Chander S & Vieth R 2005 Pilot study: potential role of vitamin D (cholecalciferol) in patients with PSA relapse after definitive therapy. Nutrition and Cancer 51 32-36. (doi:10.1207/ s15327914nc5101-5)
179. WoolcottCG,Wilkens LR,NomuraAM, Horst RL,GoodmanMT,Murphy SP, Henderson BE, Kolonel LN & Le Marchand L 2010 Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers & Prevention 19 130-134. (doi:10.1158/1055-9965. EPI-09-0475)
180. Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW & Giovannucci EL 2007 A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. Journal of the National Cancer Institute 99 1120-1129. (doi:10.1093/jnci/djm038)
181. Xu H, Posner GH, StevensonM& Campbell FC 2010 Apc(MIN) modulation of vitamin D secosteroid growth control. Carcinogenesis 31 1434-1441. (doi:10.1093/carcin/bgq098)
182. Yang K, Kurihara N, Fan K, Newmark H, Rigas B, Bancroft L, Corner G, Livote E, Lesser M, Edelmann W et al. 2008a Dietary induction of colonic tumors in a mouse model of sporadic colon cancer. Cancer Research 68 7803-7810. (doi:10.1158/0008-5472.CAN-08-1209)
183. Yang K, Lamprecht SA, Shinozaki H, Fan K, Yang W, Newmark HL, Kopelovich L, Edelmann W, Jin B, Gravaghi C et al. 2008b Dietary calcium and cholecalciferol modulate cyclin D1 expression, apoptosis, and tumorigenesis in intestine of adenomatous polyposis coli 1638N/C mice. Journal of Nutrition 138 1658-1663. (doi:10.3945/jn. 108.090985)
184. Yao S & Ambrosone CB 2012 Associations between vitamin D deficiency and risk of aggressive breast cancer in African-American women. Journal of Steroid Biochemistry and Molecular Biology. (doi:10.1016/j.jsbmb.2012.09.010)
185. Yao S, SuchestonLE,MillenAE, JohnsonCS, TrumpDL, NeslineMK,DavisW, Hong CC, McCann SE, Hwang H et al. 2011 Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoSONE 6 e17251. (doi:10.1371/journal.pone.0017251)
186. Yao S, Zirpoli G, Bovbjerg DH, Jandorf L, Hong CC, Zhao H, Sucheston LE, Tang L, Roberts M, Ciupak G et al. 2012 Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Research 14 R58. (doi:10.1186/bcr3162)
187. YoungMV, SchwartzGG,Wang L, JamiesonDP,Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF & Chen TC 2004 The prostate 25-hydroxyvitamin D-1 a-hydroxylase is notinfluenced byparathyroidhormone and calcium:implications for prostate cancer chemopreventionby vitamin D. Carcinogenesis 25 967-971. (doi:10.1093/carcin/bgh082)
188. Zhang J & Yao Z 2000 Effect of 1,25(OH)2D3 on the growth and apoptosis of breast cancer cell line MCF-7. Chinese Medical Journal 113 124-128.
189. Zheng W, Wong KE, Zhang Z, Dougherty U, Mustafi R, Kong J, Deb DK, Zheng H, Bissonnette M & Li YC 2011 Inactivation of the vitamin D receptor in APC(min/C) mice reveals a critical role for the vitamin D receptor in intestinal tumor growth. International Journal of Cancer 130 10-19. (doi:10.1002/ijc. 25992)
190. Zinser GM, McEleney K & Welsh J 2003 Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Molecular and Cellular Endocrinology 200 67-80. (doi:10.1016/S0303-7207(02)00416-1)